XIENCE Sierra: Best in Class Treatment for Patients with Diabetes

Many patients with diabetes will undergo revascularization for coronary artery disease at some point, and their risk of adverse events is higher than in nondiabetic patients.1 It is therefore critical that the stent they receive is deliverable enough to navigate their complex anatomy and can provide long-term patient safety.   

XIENCE Sierra is uniquely suited for the long, diffuse lesions and small, tapered vessels that are often found in diabetic patients. XIENCE has also demonstrated exceptional safety in diabetic patients. 

Available in Long Lengths for Small Diameters

XIENCE Sierra is available in long lengths in small diameters to provide treatment for the long, diffuse lesions that are often observed in patients with diabetes.

Available in Long Lengths for Small Diameters

XIENCE Sierra is available in long lengths in small diameters to provide treatment for the long, diffuse lesions that are often observed in patients with diabetes.

HIGHEST EXPANSION IN SMALL DIAMETERS FOR TAPERED VESSELS

XIENCE Sierra has the highest expansion capability in smaller diameter sizes, which is ideal for long, diffuse lesions in tapered vessels.

HIGHEST EXPANSION IN SMALL DIAMETERS FOR TAPERED VESSELS

XIENCE Sierra has the highest expansion capability in smaller diameter sizes, which is ideal for long, diffuse lesions in tapered vessels.

Better Pushability in Small, Calcified Lesions

Compared to both Synergy and Resolute Onyx, XIENCE Sierra requires up to 73% less force to cross the same lesion.2

Better Pushability in Small, Calcified Lesions

Compared to both Synergy and Resolute Onyx, XIENCE Sierra requires up to 73% less force to cross the same lesion.2

Multiple Trials Show Safety and Efficacy in Patients With Diabetes*

Multiple Trials Show Safety and Efficacy in Patients With Diabetes*

CTO

AP2945978-WBU Rev. A

* Data differences depicted between these trials may not be statistically significant or clinically meaningful, and different clinical trials may include differences in the patient populations.

  1. Tandjung K. TWENTE Trial. TCT 2012.
  2. Test performed by and data on file at Abbott. XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, Synergy Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5.
  3. Kaul U, et al. Last Word on DES in Diabetics: Two-Year TUXEDO Outcomes. TCT 2016.
  4. Jensen L. Five-Year Stent-Related and Patient-Related Outcomes in Patients with and without Diabetes: From the SORT OUT IV Trial. ACC 2015.
  5. Tandjung K. Clinical Outcome of Diabetic and Non-Diabetic Patients Treated with Second-Generation Zotarolimus-Eluting and Everolimus-Eluting DES: A Subgroup Analysis of the TWENTE Trial. TCT 2012.

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?
Important safety information